Dokumentdetails
ID

oai:arXiv.org:2404.01654

Thema
Computer Science - Computer Vision... Computer Science - Artificial Inte... Electrical Engineering and Systems... Electrical Engineering and Systems...
Autor
Xiang, Xiang Zhang, Zihan Ma, Jing Deng, Yao
Kategorie

Computer Science

Jahr

2024

Auflistungsdatum

10.04.2024

Schlüsselwörter
parkinson engineering ai disease science
Metrisch

Zusammenfassung

Parkinson's Disease (PD) is the second most common neurodegenerative disorder.

The existing assessment method for PD is usually the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) to assess the severity of various types of motor symptoms and disease progression.

However, manual assessment suffers from high subjectivity, lack of consistency, and high cost and low efficiency of manual communication.

We want to use a computer vision based solution to capture human pose images based on a camera, reconstruct and perform motion analysis using algorithms, and extract the features of the amount of motion through feature engineering.

The proposed approach can be deployed on different smartphones, and the video recording and artificial intelligence analysis can be done quickly and easily through our APP.

;Comment: Technical report for AI WALKUP, an APP winning 3rd Prize of 2022 HUST GS AI Innovation and Design Competition

Xiang, Xiang,Zhang, Zihan,Ma, Jing,Deng, Yao, 2024, AI WALKUP: A Computer-Vision Approach to Quantifying MDS-UPDRS in Parkinson's Disease

Dokumentieren

Öffnen

Teilen

Quelle

Artikel empfohlen von ES/IODE AI

MELAS: Phenotype Classification into Classic-versus-Atypical Presentations
presentations mitochondrial strokelike patients variability phenotype clinical melas
Protocol for the promoting resilience in stress management (PRISM) intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer
cancer quality of life anxiety depression hope coping skills communication intervention randomized ayas outcomes resilience care trial cancer prism-ac advanced